Results 11 to 20 of about 1,582,509 (353)

Vaccine Innovation Conference 2017

open access: yesJournal of Pharmacy & Pharmaceutical Sciences, 2017
Proceedings from the Vaccine Innovation Conference 2017, held May 10, 2017, at Hyatt Regency Hotel, Montréal, QC, Canada, Presented by: Vaccine Industry ...
Vaccine Industry Committee
doaj   +2 more sources

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

open access: yesNew England Journal of Medicine, 2021
Background The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a prefusion-stabilized conformation.
J. Sadoff   +29 more
semanticscholar   +1 more source

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

open access: yesThe Lancet, 2020
Summary Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic.
M. Voysey   +499 more
semanticscholar   +1 more source

Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.

open access: yesNew England Journal of Medicine, 2023
BACKGROUND Respiratory syncytial virus (RSV) is an important cause of acute respiratory infection, lower respiratory tract disease, clinical complications, and death in older adults.
A. Papi   +15 more
semanticscholar   +1 more source

Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection

open access: yesnpj Vaccines, 2021
RTS,S/AS01 is an advanced pre-erythrocytic malaria vaccine candidate with demonstrated vaccine efficacy up to 86.7% in controlled human malaria infection (CHMI) studies; however, reproducible immune correlates of protection (CoP) are elusive. To identify
Kelly E. Seaton   +16 more
doaj   +1 more source

Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.

open access: yesNew England Journal of Medicine, 2023
BACKGROUND Respiratory syncytial virus (RSV) infection causes considerable illness in older adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein-based (RSVpreF) vaccine in this population are unknown.
E. Walsh   +30 more
semanticscholar   +1 more source

A global survey of potential acceptance of a COVID-19 vaccine

open access: yesNature Medicine, 2020
Several coronavirus disease 2019 (COVID-19) vaccines are currently in human trials. In June 2020, we surveyed 13,426 people in 19 countries to determine potential acceptance rates and factors influencing acceptance of a COVID-19 vaccine.
J. Lazarus   +7 more
semanticscholar   +1 more source

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

open access: yesNew England Journal of Medicine, 2021
Background Despite high vaccine coverage and effectiveness, the incidence of symptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been increasing in Israel.
E. G. Levin   +13 more
semanticscholar   +1 more source

Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose

open access: yesnpj Vaccines, 2022
Vaccination with typhoid conjugate vaccines (TCV) is a major part of typhoid prevention. However, little is known about long-term immune persistence following vaccination with TCVs.
Maria Rosario Capeding   +19 more
doaj   +1 more source

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

open access: yesNew England Journal of Medicine, 2020
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine.
L. Jackson   +32 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy